Crossmark

From PD-L1 downregulation to biomarker-driven immunotherapy design: advancing translational application of SALL4-targeted PEN-FFW in breast cancer

Crossref DOI link: https://doi.org/10.1007/s12026-026-09774-2

Published Online: 2026-04-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vijayasimha, M. https://orcid.org/0000-0003-2038-7006
Srikanth, M. https://orcid.org/0009-0005-8488-6041
License Information

Text and Data Mining valid from 2026-04-02

Version of Record valid from 2026-04-02
More Information

Article History

Received: 30 January 2026

Accepted: 30 March 2026

First Online: 2 April 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.